November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more
November 7th, 2026VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous CancersVET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.Read more
November 6th, 2026Canakinumab Reduces Nodule Size in High-Risk Lung PrecancersIL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.Read more
November 6th, 2026EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced MelanomaEVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.Read more
November 18th, 2026Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLCThe FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.Read more
November 18th, 2026Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future CareersDeepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.Read more
November 18th, 2026Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLCLonger follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.Read more
November 17th, 2026Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLCThe CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.Read more